Evidence map›Paper›PMID 31390852›Full record

ArticleTurkish journal of medical sciences2019

Association between PPARGC1A single nucleotide polymorphisms and increased risk of nonalcoholic fatty liver disease among Iranian patients with type 2 diabetes mellitus

Leila Saremi, Shirin Lotfıpanah, Masumeh Mohammadi, Hassan Hosseinzadeh, Zahra Hosseini-Khah, Behrooz Johari, Zohreh Saltanatpour

Open access · bronzeAbstract read
In one paragraph

Article in Turkish journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Leila SaremiDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, IranORCID 0000-0003-0219-6927
Shirin LotfıpanahFarhangian University, Shahid Mofatteh Teacher Education Paradise, Tehran, IranORCID 0000-0002-4958-4401
Masumeh MohammadiDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, IranORCID 0000-0003-3889-8234
Hassan HosseinzadehDepartment of Biology, Faculty of Science, Yazd University, Yazd, IranORCID 0000-0003-0399-2642
Zahra Hosseini-KhahDepartment of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IranORCID 0000-0002-9052-8866
Behrooz JohariDepartment of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, IranORCID 0000-0003-3440-572X
Zohreh SaltanatpourDepartment of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IranORCID 0000-0002-1616-9404
Islamic Azad University, Science and Research Branch · IRTehran University of Medical Sciences · IRFarhangian University · IRYazd University · IRZanjan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Environmental and genetic factors may play a major role in the development of nonalcoholic fatty liver disease (NAFLD) among people with obesity and type 2 diabetes mellitus. Based on the fact that PGC-1α, as the protein encoded by the PPARGC1A gene, plays a key role in energy metabolism pathways, it has been hypothesized that polymorphisms within the PPARGC1Agene may be associated with increased risks of NAFLD. Thus, this study was designed to evaluate the Gly482Ser polymorphism (rs8192678) within the PPARGC1A gene and its association with the increased risk of NAFLD in Iranian patients with type 2 diabetes. Materials and methods: A total of 145 NAFLD patients with a history of type 2 diabetes and 145 healthy control subjects were included in the study. Gly482Ser polymorphism genotyping was done using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique. Results: The results showed a significant difference between the PPARGC1A Gly482Serpolymorphism in NAFLD patients and the healthy controls. Accordingly, the AA genotype and A allele were increased in the NAFLD patients when compared to the healthy controls. However, no significant correlation was observed between the Gly482Ser polymorphism and the physiological and biochemical parameters. Conclusion: Based on the results, the AA genotype, which is associated with the insertion of Ser, can be considered as a risk factor for the development of NAFLD in Iranian patients with diabetes type 2.

Indexed as

Non-alcoholic Fatty Liver DiseaseAdultCase-Control StudiesDiabetes Mellitus, Type 2FemaleGenetic Predisposition to DiseaseHumansIranMaleMiddle AgedPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPolymorphism, Single NucleotidePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanGly482Ser polymorphismNonalcoholic fatty liver diseasePPARGC1A genetype 2 diabetes

Identifiers

PMID31390852
PMCPMC7018303
OpenAlexW2967029211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.